From biomarker to surrogate outcome in osteoarthritis - What are the challenges?

Journal of Rheumatology

Volumn 32, Issue 6, 2005, Pages 1142-1143

  Lohmander, L Stefan ^a   Eyre, David R ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ARTICULAR CARTILAGE; AWARENESS; BODY FLUID; CONFERENCE PAPER; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DRUG SCREENING; HUMAN; OBESITY; OSTEOARTHRITIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CONTENT; PROTEOMICS; PUBLIC HEALTH; QUALITY OF LIFE; VALIDATION PROCESS;

BIOLOGICAL MARKERS; DRUG DESIGN; ENDPOINT DETERMINATION; HUMANS; OSTEOARTHRITIS; TREATMENT OUTCOME;

EID: 20444487699     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (5)

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
2. Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability. Arthritis Rheum 2004;50:1709-20.
3. Mildvan D, Landay A, De Gruttola V, Machado SG, Kagan J. An approach to the validation of markers for use in AIDS clinical trials. Clin Infect Dis 1997;24:764-74.
4. De Gruttola V, Fleming TR, Lin DY, Coombs R. Perspective: validating surrogate markers - are we being naïve? J Infect Dis 1997;175:237-46.
5. Lohmander LS, Poole AR. Defining and validating the clinical role of biomarkers in osteoarthritis. In: Brandt KD, Doherty M, Lohmander LS, editors. Osteoarthritis. 2nd ed. Oxford: Oxford University Press; 2003:468-77.